KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research ...
NanoString is an Established Leader and Valuable Innovator in Gene Expression Profiling and Spatial Transcriptomics for Scientific and Clinical Research in Healthcare Under the asset purchase ...
Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna Assay is an in vitro diagnostic tool that utilizes gene expression data weighted together ...
10x Genomics has begun commercial shipments of a new 5,000–plex gene expression panel that increases plex by an order of magnitude over previous panels, a month after announcing the launch of the ...
NanoString Technologies, Inc announced positive results from the first clinical validation study of its first in vitro diagnostic product, a breast cancer assay based on the PAM50 gene expression ...
NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results